Flexible and rapid construction of viral chimeras applied to hepatitis C virus by McClure, Patrick C. et al.
Downloaded from www.microbiologyresearch.org by
IP:  128.243.38.220
On: Fri, 28 Jul 2017 12:24:45
Short
Communication
Flexible and rapid construction of viral chimeras
applied to hepatitis C virus
C. Patrick McClure, Richard A. Urbanowicz, Barnabas J. King,
Sara Cano-Crespo, Alexander W. Tarr and Jonathan K. Ball
Correspondence
C. Patrick McClure
patrick.mcclure@nottingham.ac.
uk
Jonathan K. Ball
jonathan.ball@nottingham.ac.uk
Received 1 March 2016
Accepted 20 June 2016
School of Life Sciences and NIHR Nottingham Digestive Diseases Biomedical Research Unit, The
University of Nottingham, Nottingham University Hospitals NHS Trust, Nottingham, UK
A novel and broadly applicable strategy combining site-directed mutagenesis and DNA assembly
for constructing seamless viral chimeras is described using hepatitis C virus (HCV) as an
exemplar. Full-length HCV genomic cloning cassettes, which contained flexibly situated
restriction endonuclease sites, were prepared via a single, site-directed mutagenesis reaction
and digested to receive PCR-amplified virus envelope genes by In-Fusion cloning. Using this
method, we were able to construct gene-shuttle cassettes for generation of cell culture-
infectious JFH-1-based chimeras containing genotype 1–3 E1E2 genes. Importantly, using this
method we also show that E1E2 clones that were not able to support cell entry in the HCV
pseudoparticle assay did confer entry when shuttled into the chimeric cell culture chimera
system. This method can be easily applied to other genes of study and other viruses and, as
such, will greatly simplify reverse genetics studies of variable viruses.
The genetic diversity of viruses often demands representa-
tion of many isolates in experimental systems in order to
comprehensively phenotype an organism and to probe
efficacy of prophylactic and therapeutic intervention
(Burton et al., 2012; Das et al., 2013; deCamp et al., 2014;
Imhof & Simmonds, 2010, 2011; Pietschmann et al.,
2006). Reverse genetics systems developed to study host–
pathogen interaction are typically constructed by PCR
amplification and gene or genome cloning into plasmid
vectors (Das et al., 2013; deCamp et al., 2014; Dutta et al.,
2013; Imhof & Simmonds, 2010, 2011; Lindenbach et al.,
2005; Pietschmann et al., 2006; Urbanowicz et al., 2015).
This involves a protracted multistep process, utilizing it-
erative rounds of restriction endonuclease (RE) digestion,
stitch/fusion PCR and subsequent enzymatic modifications
(Edmonds et al., 2010; Imhof & Simmonds, 2010; Linden-
bach et al., 2005; Steinmann et al., 2013). Each amplifica-
tion and ligation reaction can be error-prone, frequently
requiring corrective back-mutation steps. Such workflows
rely on either naturally occurring RE sites, which are often
suboptimally located, or on the generation of novel RE
sites, which can impact on important biological properties
such as RNA structure (You et al., 2004) even when
mutations are synonymous. Reliance on RE-based cloning
can also be adversely affected by the presence of internal
RE sites in the target gene, due to natural genetic variation
of the virus. These experimental difficulties have limited
the range of reference phenotyping systems available,
despite their crucial importance in vaccine and treatment
development and monitoring (Burton et al., 2012;
deCamp et al., 2014; Imhof & Simmonds, 2011).
Hepatitis C virus (HCV) displays extensive genetic het-
erogeneity, particularly in the genes encoding envelope
glycoproteins (E1 and E2). Studies of the impact of natu-
ral variation on antiviral sensitivity (Imhof & Simmonds,
2010) or on neutralization sensitivity to mAbs (Ball et al.,
2014) or vaccine-sera (Chmielewska et al., 2014), have
suffered significantly from the drawbacks described above
and the current lack of culture systems for wild-type,
patient-derived isolates. This has resulted in the develop-
ment of drug sensitivity phenotyping methods that
require significant genetic manipulation (Imhof & Sim-
monds, 2010, 2011) or the use of very small panels of
infectious virus that are potentially unrepresentative of
patient-derived virus for antibody studies (Keck et al.,
2013).
DNA assembly technology (Irwin et al., 2012) was therefore
employed to develop a novel strategy for generating chi-
meric molecular cloning cassettes. Using this method, a
panel of 49 functional full-length HCV genomes containing
patient-derived E1E2 has been derived. This has revealed
novel insights into their function that was hitherto impos-
sible using existing phenotyping resources, such as pseudo-
particle (pp) assays. Importantly, this approach can be
The GenBank accession numbers for the HCV E1E2 nucleotide sequen-
ces described in this study are given in Table S2.
Supplementary Material is available with the online version of this paper.
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widely used in reverse genetics studies of any genetically
variable virus, or indeed other organisms, employing plas-
mid constructs.
Sequence files of parental HCV genotype 1 (Gt1) Bi-Gluc-
H77C(1a)/JFH (T2700C, A4080T) (Reyes-del Valle et al.,
2012) and Gt2 J6/JFH-1 (Lindenbach et al., 2005) chimeric
clones were screened for RE sites using the online NEBcut-
ter 2.0 tool [http://nc2.neb.com/NEBcutter2/, New England
Biolabs (NEB)]. FseI was identified in both parental clones
as a non-cutting RE site with 3¢ overhangs, and therefore
leaving the smallest footprint in standard In-Fusion cloning
(Clontech Laboratories Inc), retaining only two bases (5¢
GG, 3¢ CC) of the RE site post-cloning at each chimeric
junction. The desired chimeric junction points at the 5¢ end
of the signal peptide of E1 and the 3¢ C terminus of E2,
were scanned for the retained GG and CC dinucleotide
motifs, respectively, and candidate sites located (Fig. 1a). In
the absence of convenient dinucleotide motifs, enzymatic
blunting of 5¢ overhangs could be performed to extend
choice of cloning sites to single bases. The reliance on the
presence of only the double-stranded remnant at the 3¢
overhanging RE site thus increases potential chimeric junc-
tion options by several orders of magnitude.
Site-directed mutagenesis (SDM) primers were then
designed using the online NEB BaseChanger tool (http://
nebasechanger.neb.com/) to simultaneously knockout the
parental E1E2 sequence between the GG and CC junction
points and introduce the 4 bp motif CCGG to create a com-
plete FseI RE site (GGCCGGCC, Fig. 1b; primers 1, 2, 14
and 15, Table S1, available in the online Supplementary
Material). All primers were synthesized by Eurofins. SDM
and transformation into Escherichia coli with ampicillin
selection was carried out using the Q5 SDM kit (NEB)
according to the manufacturer’s protocolusing primers 3, 4,
16 and 17 (Table S1). Verified plasmid minipreps of
DE1E2FseI E1E2 cassettes were RE digested overnight with
FseI (NEB, Fig. 1c) and then column purified.
Creating viable HCV chimeras requires the viral core and
NS2 genes to be genotype-matched (Lindenbach et al.,
2005; Mateu et al., 2008). A DCore-NS2AfeI cassette was
therefore created to further test the strategy and facilitate
the construction of chimeras with patient-derived Gt3
E1E2. J6/JFH-1(Lindenbach et al., 2005) was screened in
NEBcutter 2.0 for non-cutting RE sites and the component
termini of AfeI were identified as naturally occurring at the
desired chimeric junctions at the 5¢ start of core (AGC) and
the 3¢ end of NS2 (GCT, Fig. 1h). Whilst the chosen paren-
tal HCV genome presented a fortuitous mutagenesis option,
the RE digest mapping described above could simply be
applied to select a novel non-cutting site, even the same
FseI as used in the E1E2 region as this would be lost in the
first DNA assembly cloning reaction. SDM primers 23 and
24 (Table S1) were then designed in NEB BaseChanger to
remove the Core-NS2 sequence between the AGC and GCT
junction points to create a complete AfeI RE site
(AGCGCT). SDM and clone verification was performed
(with insert screening primers 25 and 26, Table S1) to create
a DCore-NS2 AfeI JFH-1 plasmid cassette (Fig. 1i). This
process essentially removed the J6 component present in
the parental chimera. The DCore-NS2 AfeI cassette was RE
digested with AfeI (Thermo Fisher Scientific) and reverted
to its parental wild-type using J6/JFH-1 core-NS2 amplified
with PCR primers 27 and 28 (Table S1) by In-Fusion clon-
ing (see below), to confirm unaltered phenotype. To create
a novel HCV Gt3 DE1E2FseI cassette, a Core-NS2 Gt3
sequence (GenBank accession number GU814263.1, Gott-
wein et al., 2007) was synthesized (Gene Strings, Invitrogen)
already containing the above described DE1E2FseI modifi-
cation and 15 bp terminal homology to the AfeI RE-digested
DCore-NS2 AfeI cassette and cloned by In-Fusion (see
below) into the DCore-NS2 AfeI JFH-1 plasmid cassette
(Fig. 1j). This DE1E2FseI S52/JFH-1 cassette was verified
using primers 25 and 26 and RE digested with FseI for In-
Fusion cloning (Fig. 1c).
Forty-nine HCV E1E2 isolates (see Table S2) were derived
from patients as previously described (Lavillette et al., 2005;
Owsianka et al., 2005; Urbanowicz et al., 2015). DNA clone
sequences were aligned using CLUSTALW, as implemented in
the MEGA version 6 software (Tamura et al., 2013), and
complementary primers were designed to amplify the
region between the aligned GG/CC junction points identi-
fied above (primers 5–13, 18–22 and 31–33, Table S1). Pri-
mers were also tagged with a 15 base region complementary
to the appropriate end of the digested knockout cassette,
ending in the GG dinucleotide motif (Fig. 1d). Plasmid
template was amplified using the Q5 high-fidelity DNA
polymerase (NEB, Fig. 1e) and PCR products inserted with-
out purification into the cassette by In-Fusion cloning as
per the manufacturer’s instructions (Fig. 1f).
In-Fusion reaction transformants were screened for pres-
ence of inserted DNA by colony PCR using cassette-specific
primers (3 and 4, 16 and 17 and 29 and 30 for genotypes 1,
2 and 3 respectively, Table S1). Putative chimeric colony
PCR product sequences were verified against parental
DE1E2FseI E1E2 plasmid and patient-derived E1E2 sequen-
ces in MEGA6. Confirmed chimeric plasmids (Fig. 1g) were
prepared and linearized overnight with XbaI
(Thermo Fisher Scientific), column purified and used as a
template to generate HCV RNA transcripts with a
MEGAscript T7 kit (Thermo Fisher Scientific). RNA tran-
scripts were column purified using a QIAamp Viral RNA
Mini Kit (Qiagen) and eluted in DEPC–treated water. Elec-
troporation and cell culture was performed as previously
described in duplicate (Lindenbach et al., 2005).
To confirm no off-target deleterious PCR errors had
occurred in the DE1E2FseI cassette constructs, preliminary
wild-type revertant clones were created prior to the creation
of chimeric clones and tested alongside the parental clone
in the cell culture system. Parental wild-type E1E2 was rein-
serted into the cassettes by In-Fusion cloning with primers
5 and 7 (Gt 1, Table S1) and 19 and 22 (Gt2, Table S1) to
confirm unaltered phenotype; alternatively full plasmid
2188 Journal of General Virology 97
C. P. McClure and others
Downloaded from www.microbiologyresearch.org by
IP:  128.243.38.220
On: Fri, 28 Jul 2017 12:24:45
sequencing could be undertaken. Wild-type infectivity titres
were demonstrated in cell culture for each of the wild-type
reverted cassettes (data not shown).
The above strategy was initially applied to the previously
described J6/JFH-1 parental chimera (Lindenbach et al.,
2005; Mateu et al., 2008), generating a DE1E2 cassette to
receive Gt2 E1E2s. Initially six patient-derived Gt2 E1E2s
were selected based on their functionality in the pp assay
(Lavillette et al., 2005; Tarr et al., 2011; Urbanowicz et al.,
2015). All of these isolates were able to replicate and pro-
duced infectious virus at all three sampled time points (24,
96 and 192 h post electroporation, Fig. 2b).
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Fig. 1. DE1E2FseI and DCore-NS2 AfeI HCV cassette and chimera construction schematic. The E1E2 region of the full gen-
omic parental clone is deleted between the naturally occurring non-overhanging termini of an RE site not found in the parental
clone [FseI here, codons 171 to 742 (H77) or 748 (J6)], and replaced with the complete novel RE site by a single SDM reac-
tion (a). The DE1E2FseI plasmid cassette (b) is RE digested at the novel FseI RE site (c) and assembled by In-Fusion cloning
(f) with patient-derived E1E2 (d) amplified with 15 bp terminal homology to the digested cassette (e). The resulting chimera
contains only wild-type sequence from both parental full-length genome and patient-derived E1E2 isolates (g). Similarly, to
generate intergenotypic cassettes the Core-NS2 region of the full genomic parental clone is deleted between the naturally
occurring non-overhanging termini of an RE site absent in the parental clone (h, AfeI here, codons 2–1031), and replaced with
the complete novel RE site by a single SDM reaction (i). The DCore-NS2 AfeI plasmid cassette is RE digested at the novel
AfeI site and assembled by In-Fusion cloning with in vitro synthesized Core-NS2 with 15 bp terminal homology to the digested
clone and E1E2 region replaced with a unique RE site (FseI here, pre-deleting codons 171–734). The resulting DE1E2FseI
cassette (j) can then receive patient-derived E1E2 of the same genotype as the inserted core and NS2 genes to create func-
tional intergenotypic chimeras (c–g).
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Fig. 2. Forty-nine HCV E1E2 isolates show measurable infectivity in full-length chimeric HCV within 96 h of electroporation inde-
pendent of function in a pseudoparticle assay. Focus forming units (FFU) were calculated from NS5a stained cells for each iso-
late at 24, 96 and 192 h time points. (a) Thirty-two genotype (Gt) 1 isolates, (b) 12 Gt2 isolates and (c) 5 Gt3 isolates are shown
alongside the reference strains H77/JFH (Gt1, purple open circle), J6/JFH (Gt2, green open diamond) and JFH-1 (parental chi-
mera; Gt2, green filled diamond). (d) FFU calculated for the 96 h time point for all 49 chimeras plotted against the isolate’s ability
to produce infectious pseudoparticles above the limit of detection in a retroviral pseudotype assay (closed objects, termed pp
+ve) or not (open objects, termed pp –ve). (e) Eight isolates with titres ranging from 1.2103 to 1.1106 FFU ml 1 were neutral-
ized by an increasing concentration of anti-CD81 mAb. Mean±SEM shown for each category.
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Similarly ten Gt1 and five Gt3 E1E2 clones, which had
previously been shown to confer entry in the HCVpp
assay, were cloned into the H77/JFH-1 and S52/JFH-1
cassettes, respectively. Using this approach all of the
clones were infectious (Fig. 2a, c). This confirms that
infectious chimera construction relies on the presence of
genotype matched core-NS2 genome segments, as has
been described previously (Gottwein et al., 2007; Linden-
bach et al., 2005; Mateu et al., 2008; Pietschmann et al.,
2006).
Fig. 3.Maximum likelihood molecular phylogenetic analysis of HCV E1/E2 nucleotide sequences. The evolutionary history of the
patient-isolated HCV E1/E2 genes cloned into chimeric HCVcc was inferred by using the maximum likelihood method based on
the general time reversible model. The tree with the highest log likelihood is shown. Initial tree(s) for the heuristic search were
obtained automatically by applying neighbour-joining and BioNJ algorithms to a matrix of pairwise distances estimated using the
maximum composite likelihood approach, and then selecting the topology with superior log likelihood value. The tree is drawn to
scale, with branch lengths measured in the number of substitutions per site. The analysis involved 49 E1/E2 gene sequences
(blue diamond) derived from 25 individual patients, and 15 genotype reference nucleotide sequences (red circle). Codon posi-
tions included were 1st + 2nd+3rd+ non-coding. All positions containing gaps and missing data were eliminated. There were a
total of 1649 positions in the final dataset. Evolutionary analyses were conducted in MEGA7 (Kumar et al., 2016).
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The analysis was then extended to include E1E2 isolates that
have been classed as non-functional in the pp assay (below
the limit of detection, data not shown). Again, all 28
patient-derived E1E2 isolates (22 Gt1 and six Gt2) were
both replication competent and produced infectious virus at
the three sampled time points (Fig. 2a, b, c, d). To rule out
the possibility of exosome transmission (Bukong et al.,
2014), we performed a neutralization assay with an anti-
CD81 antibody (JS-81, BD Biosciences) on a select number
of clones representative of high, medium and low virus titre,
as previously described (Tarr et al., 2013). Infectivity of all
clones tested was completely blocked at 10 µg ml 1
(Fig. 2e).
The E1E2 clones used for chimera generation were all
obtained from the UK. Despite their restricted geographical
sampling they demonstrated a large degree of intra-
genotype and subtype nucleotide diversity (Fig. 3). The
intra-sample variability for the subtype 1a, 1b and 3a and
the Gt2 clusters were 10.2, 11.6, 6.6 and 31.1%, respec-
tively, which is similar to that reported in previous phyloge-
netic studies (Brown et al., 2007).
The inclusion of five Gt3 isolates is a leap forward and
begins to reduce the paucity of isolates from this geno-
type. Previous studies have shown that patients harbour a
high frequency of HCVpp entry-deficient E1E2 (Lavillette
et al., 2005). Crucially, the data presented here shows that
the HCVpp system is not a good predictor of E1E2-medi-
ated cell entry and this technique allows for a more
diverse panel of E1E2s to be investigated. This technique
has thus generated a panel of infectious HCV chimeras
that is significantly larger than all the isolates produced to
date and expanding it even further has now become read-
ily achievable. Although the infectivity of some clones was
low, it was still reproducible and at detection levels that
would allow further phenotypic analysis, such as the neu-
tralization assays presented in Fig. 2e. It is possible that
further passage of the chimeras could lead to improved
infectivity through the acquisition of adaptive mutations
(Gottwein et al., 2007; Mateu et al., 2008), but care would
be needed to ensure that these did not occur within the
E1E2 coding region, or indeed other target regions, under
study.
In summary, our method facilitates flexible and rapid crea-
tion of diverse, functional and seamless molecular chimeras
for development and testing of novel therapeutics. This
method can also be applied to personalized medicine by
pre-testing patient-specific viruses for treatment sensitivity
(Angus et al., 2003; Imhof & Simmonds, 2011). Import-
antly, location of the cloning site is only limited by the need
to identify an RE site not contained in the parental cassette
backbone and, given that any RE digest overhang is
removed during the cloning step, targeting to single nucleo-
tide positions is possible. This gives a degree of flexibility
and ease hitherto unheard of for a single-step chimeric
reverse genetics procedure.
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